Grifols (NASDAQ:GRFS) Sets New 12-Month Low – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS)’s stock price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $7.26 and last traded at $7.2870, with a volume of 409443 shares trading hands. The stock had previously closed at $7.40.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Weiss Ratings raised shares of Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Zacks Research downgraded Grifols from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. Finally, Wall Street Zen cut shares of Grifols from a “buy” rating to a “hold” rating in a report on Monday, May 18th. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $10.00.

Grifols Trading Down 1.7%

The company has a quick ratio of 0.85, a current ratio of 2.47 and a debt-to-equity ratio of 1.16. The company has a market capitalization of $4.95 billion, a PE ratio of 38.29, a price-to-earnings-growth ratio of 0.29 and a beta of 0.65. The stock’s 50 day moving average is $7.93 and its two-hundred day moving average is $8.52.

Grifols (NASDAQ:GRFS) last posted its quarterly earnings results on Saturday, February 14th. The biotechnology company reported $0.38 EPS for the quarter. The business had revenue of $2.32 billion during the quarter. Grifols had a net margin of 5.54% and a return on equity of 6.21%. As a group, sell-side analysts predict that Grifols, S.A. will post 1.06 EPS for the current fiscal year.

Hedge Funds Weigh In On Grifols

A number of large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its position in Grifols by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 1,212 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Grifols by 50.3% during the first quarter. PNC Financial Services Group Inc. now owns 8,961 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 2,998 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Grifols by 127.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 4,604 shares during the last quarter. Allworth Financial LP raised its holdings in shares of Grifols by 15.7% in the fourth quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock worth $75,000 after buying an additional 1,096 shares during the last quarter. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Grifols during the second quarter worth $95,000.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.